{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:39:28Z","timestamp":1787956768160,"version":"build-2784847793"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40744-021-00290-3","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T19:03:33Z","timestamp":1614366213000},"page":"529-539","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Treatment Patterns, Disease Burden, and Outcomes in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica: A Real-World, Electronic Health Record-Based Study of Patients in Clinical Practice"],"prefix":"10.1007","volume":"8","author":[{"given":"Gary","family":"Craig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Knapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob","family":"Salim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini V.","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Michalska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"290_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jaut.2014.01.017","volume":"8\u201349","author":"G Nesher","year":"2014","unstructured":"Nesher G. The diagnosis and classification of giant cell arteritis. J Autoimmun. 2014;8\u201349:73\u20135.","journal-title":"J Autoimmun"},{"issue":"1","key":"290_CR2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12877-019-1225-9","volume":"19","author":"MA Gonzalez-Gay","year":"2019","unstructured":"Gonzalez-Gay MA, Ortego-Jurado M, Ercole L, Ortego-Centeno N. Giant cell arteritis: is the clinical spectrum of the disease changing? BMC Geriatr. 2019;19(1):200.","journal-title":"BMC Geriatr"},{"issue":"390","key":"290_CR3","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/S0140-6736(17)31825-1","volume":"7","author":"MA Gonzalez-Gay","year":"2017","unstructured":"Gonzalez-Gay MA, Matteson EL, Castaneda S. Polymyalgia rheumatica. Lancet. 2017;7(390):1700\u201312.","journal-title":"Lancet"},{"issue":"3","key":"290_CR4","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/art.30155","volume":"63","author":"CS Crowson","year":"2011","unstructured":"Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011;63(3):633\u20139.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"290_CR5","first-page":"1694","volume":"29","author":"MF Doran","year":"2002","unstructured":"Doran MF, Crowson CS, O\u2019Fallon WM, Hunder GG, Gabriel SE. Trends in the incidence of polymyalgia rheumatica over a 30-year period in Olmsted County, Minnesota, USA. J Rheumatol. 2002;29(8):1694\u20137.","journal-title":"J Rheumatol"},{"issue":"1","key":"290_CR6","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13075-017-1479-6","volume":"19","author":"LK Brekke","year":"2017","unstructured":"Brekke LK, Diamantopoulos AP, Fevang BT, Abetamus J, Espero E, Gjesdal CG. Incidence of giant cell arteritis in Western Norway 1972\u20132012: a retrospective cohort study. Arthritis Res Ther. 2017;19(1):278.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"290_CR7","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/acr.22429","volume":"67","author":"H Petri","year":"2015","unstructured":"Petri H, Nevitt A, Sarsour K, Napalkov P, Collinson N. Incidence of giant cell arteritis and characteristics of patients: data-driven analysis of comorbidities. Arthritis Care Res (Hoboken). 2015;67(3):390\u20135.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"290_CR8","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1136\/annrheumdis-2018-213883","volume":"77","author":"RJ Partington","year":"2018","unstructured":"Partington RJ, Muller S, Helliwell T, Mallen CD, Abdul SA. Incidence, prevalence and treatment burden of polymyalgia rheumatica in the UK over two decades: a population-based study. Ann Rheum Dis. 2018;77(12):1750\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"290_CR9","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1002\/art.24459","volume":"61","author":"MA Gonzalez-Gay","year":"2009","unstructured":"Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009;61(10):1454\u201361.","journal-title":"Arthritis Rheum"},{"issue":"22","key":"290_CR10","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1001\/jama.2016.5444","volume":"315","author":"F Buttgereit","year":"2016","unstructured":"Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA. 2016;315(22):2442\u201358.","journal-title":"JAMA"},{"key":"290_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","volume":"79","author":"B Hellmich","year":"2020","unstructured":"Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79:19\u201330.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"290_CR12","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/ICU.0000000000000201","volume":"26","author":"SJ Almarzouqi","year":"2015","unstructured":"Almarzouqi SJ, Morgan ML, Lee AG. Treatment of giant cell arteritis. Curr Opin Ophthalmol. 2015;26(6):469\u201375.","journal-title":"Curr Opin Ophthalmol"},{"issue":"9","key":"290_CR13","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1136\/bjo.85.9.1061","volume":"85","author":"CC Chan","year":"2001","unstructured":"Chan CC, Paine M, O\u2019Day J. Steroid management in giant cell arteritis. Br J Ophthalmol. 2001;85(9):1061\u20134.","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"290_CR14","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","volume":"74","author":"C Dejaco","year":"2015","unstructured":"Dejaco C, Singh YP, Perel P, et al. Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2015;74(10):1799\u2013807.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"290_CR15","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1093\/rheumatology\/keq039a","volume":"49","author":"B Dasgupta","year":"2010","unstructured":"Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49(8):1594\u20137.","journal-title":"Rheumatology (Oxford)"},{"key":"290_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40744-018-0112-8","volume":"5","author":"S Gale","year":"2018","unstructured":"Gale S, Wilson JC, Chia J, et al. Risk associated with cumulative oral glucocorticoid use in patients with giant cell arteritis in real-world databases from the USA and UK. Rheumatol Ther. 2018;5:1\u201314.","journal-title":"Rheumatol Ther"},{"issue":"6","key":"290_CR17","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.semarthrit.2016.11.006","volume":"46","author":"JC Wilson","year":"2017","unstructured":"Wilson JC, Sarsour K, Collinson N, et al. Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): a nested case-control analysis. Semin Arthritis Rheum. 2017;46(6):819\u201327.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"290_CR18","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.semarthrit.2016.05.009","volume":"46","author":"MS Broder","year":"2016","unstructured":"Broder MS, Sarsour K, Chang E, et al. Corticosteroid-related adverse events in patients with giant cell arteritis: a claims-based analysis. Semin Arthritis Rheum. 2016;46(2):246\u201352.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"290_CR19","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1136\/ard.2009.114579","volume":"69","author":"MC van der Goes","year":"2010","unstructured":"van der Goes MC, Jacobs JW, Boers M, et al. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2010;69(6):1015\u201321.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"290_CR20","doi-asserted-by":"publisher","first-page":"e001003","DOI":"10.1136\/rmdopen-2019-001003","volume":"5","author":"S Monti","year":"2019","unstructured":"Monti S, \u00c1gueda AF, Luqmani RA, et al. Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. RMD Open. 2019;5(2):e001003.","journal-title":"RMD Open"},{"issue":"1","key":"290_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","volume":"79","author":"B Hellmich","year":"2019","unstructured":"Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2019;79(1):19\u201330.","journal-title":"Ann Rheum Dis"},{"key":"290_CR22","first-page":"116223","volume-title":"Kelley's textbook of rheumatology","author":"GC Hunder","year":"2001","unstructured":"Hunder GC, et al. Giant cell arteritis and polymyalgia rheumatica. In: Ruddy S, HarrisSledge EDCB, et al., editors. Kelley\u2019s textbook of rheumatology. 6th ed. Philadelphia: WB Saunders and Company; 2001. p. 116223.","edition":"6"},{"key":"290_CR23","first-page":"404","volume-title":"Vasculitidies","author":"C Weyand","year":"2008","unstructured":"Weyand C, Goronzy J. Primer on the rheumatics diseases. In: Klippel J, Stone J, Crofford L, White P, editors. Vasculitidies. New York: Springer; 2008. p. 404."},{"issue":"3","key":"290_CR24","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/rheumatology\/keu329","volume":"54","author":"F Muratore","year":"2015","unstructured":"Muratore F, Kermani TA, Crowson CS, et al. Large-vessel giant cell arteritis: a cohort study. Rheumatology (Oxford). 2015;54(3):463\u201370.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"290_CR25","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.3899\/jrheum.120511","volume":"39","author":"O Espitia","year":"2012","unstructured":"Espitia O, N\u00e9el A, Leux C, et al. Giant cell arteritis with or without aortitis at diagnosis. A retrospective study of 22 patients with long-term follow-up. J Rheumatol. 2012;39(11):2157\u201362.","journal-title":"J Rheumatol"},{"key":"290_CR26","unstructured":"de Boysson H, Liozon E, Ly KH, Dumont A, Delmas C, Aouba A. The different clinical patterns of giant cell arteritis. Clin Exp Rheumatol. 2019;37 Suppl 117(2):57\u201360."},{"key":"290_CR27","first-page":"w14661","volume":"148","author":"CT Berger","year":"2018","unstructured":"Berger CT, Sommer G, Aschwanden M, Staub D, Rottenburger C, Daikeler T. The clinical benefit of imaging in the diagnosis and treatment of giant cell arteritis. Swiss Med Wkly. 2018;148:w14661.","journal-title":"Swiss Med Wkly"},{"issue":"Suppl-2","key":"290_CR28","doi-asserted-by":"publisher","first-page":"ii32","DOI":"10.1093\/rheumatology\/kex424","volume":"57","author":"MJ Koster","year":"2018","unstructured":"Koster MJ, Matteson EL, Warrington KJ. Large-vessel giant cell arteritis: diagnosis, monitoring and management. Rheumatology (Oxford). 2018;57(Suppl-2):ii32-42.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"290_CR29","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00296-017-3874-3","volume":"38","author":"K Albrecht","year":"2018","unstructured":"Albrecht K, Huscher D, Buttgereit F, et al. Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database. Rheumatol Int. 2018;38(4):569\u201377.","journal-title":"Rheumatol Int"},{"issue":"2 Suppl 89","key":"290_CR30","first-page":"S-98","volume":"33","author":"A Chandran","year":"2015","unstructured":"Chandran A, Udayakumar PD, Kermani TA, Warrington KJ, Crowson CS, Matteson EL. Glucocorticoid usage in giant cell arteritis over six decades (1950 to 2009). Clin Exp Rheumatol. 2015;33(2 Suppl 89):S-98-102.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"290_CR31","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/acr.23320","volume":"70","author":"I Shbeeb","year":"2018","unstructured":"Shbeeb I, Challah D, Raheel S, Crowson CS, Matteson EL. Comparable rates of glucocorticoid-associated adverse events in patients with polymyalgia rheumatica and comorbidities in the general population. Arthritis Care Res (Hoboken). 2018;70(4):643\u20137.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"290_CR32","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/art.11388","volume":"49","author":"A Proven","year":"2003","unstructured":"Proven A, Gabriel SE, Orces C, O\u2019Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum. 2003;49(5):703\u20138.","journal-title":"Arthritis Rheum"},{"key":"290_CR33","unstructured":"Best JH, Kong A, Smith D, Abbass I, Michalska M (2018) Healthcare cost of potential glucocorticoid-associated adverse events in patients with giant cell arteritis [abstract]. Arthritis Rheumatol 70"},{"issue":"6","key":"290_CR34","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","volume":"75","author":"C Strehl","year":"2016","unstructured":"Strehl C, Bijlsma JW, de Wit M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016;75(6):952\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"290_CR35","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317\u201328.","journal-title":"N Engl J Med"},{"issue":"10031","key":"290_CR36","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","volume":"387","author":"PM Villiger","year":"2016","unstructured":"Villiger PM, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10031):1921\u20137.","journal-title":"Lancet"},{"issue":"10","key":"290_CR37","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1002\/art.39740","volume":"68","author":"L Lally","year":"2016","unstructured":"Lally L, Forbess L, Hatzis C, Spiera R. Brief Report: A Prospective open-label phase IIa trial of tocilizumab in the treatment of polymyalgia rheumatica. Arthritis Rheumatol. 2016;68(10):2550\u20134.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"290_CR38","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1136\/annrheumdis-2015-208742","volume":"75","author":"V Devauchelle-Pensec","year":"2016","unstructured":"Devauchelle-Pensec V, Berthelot JM, Cornec D, et al. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Ann Rheum Dis. 2016;75(8):1506\u201310.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"290_CR39","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1111\/1756-185X.13723","volume":"22","author":"K Chino","year":"2019","unstructured":"Chino K, Kondo T, Sakai R, et al. Tocilizumab monotherapy for polymyalgia rheumatica: a prospective, single-center, open-label study. Int J Rheum Dis. 2019;22(12):2151\u20137.","journal-title":"Int J Rheum Dis"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-021-00290-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40744-021-00290-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-021-00290-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T14:13:21Z","timestamp":1616595201000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40744-021-00290-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["290"],"URL":"https:\/\/doi.org\/10.1007\/s40744-021-00290-3","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,26]]},"assertion":[{"value":"24 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}